---
title: "Shield Therapeutics Grants Share Options to New CEO to Strengthen Market Position"
date: "2025-02-13 15:28:37"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart PortfolioShield Therapeutics ( (GB:STX) ) has..."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1911898180-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

Shield Therapeutics ( [(GB:STX)](https://www.tipranks.com/stocks/gb:stx) ) has issued an update.

Shield Therapeutics announced the grant of share options to its new CEO, Anders Lundstrom, under its Retention and Performance Share Plan. This move is part of Lundstrom’s onboarding process, providing him with options over 5,000,000 ordinary shares, equivalent to approximately 0.5% of the total AIM securities in issue. The grant aims to align leadership incentives with the company’s long-term goals and is expected to reinforce the company’s strategic positioning in the iron deficiency treatment market.

**More about Shield Therapeutics**

Shield Therapeutics plc is a commercial stage specialty pharmaceutical company focusing on addressing iron deficiency through its innovative product, ACCRUFeR®/FeRACCRU® (ferric maltol). This product addresses a significant unmet need for patients with iron deficiency, with or without anemia. Shield has launched ACCRUFeR® in the U.S. with Viatris Inc. and has licensing agreements with several companies for its commercialization in Europe, Asia, and Canada.

**YTD Price Performance:** 37.04%

**Average Trading Volume:** 2,933,324

**Technical Sentiment Consensus Rating:** Buy

**Current Market Cap:** £36.46M

See more insights into STX stock on [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/gb:stx/stock-analysis).

Trending Articles:
------------------

* [Amazon and Google-Backed Anthropic Says Revenue Could Reach $34.5B in 2027](https://www.tipranks.com/news/amazon-and-google-backed-anthropic-says-revenue-could-reach-34-5b-in-2027)
* [‘This Is a No-Go Zone,’ Says Investor About Palantir Stock](https://www.tipranks.com/news/this-is-a-no-go-zone-says-investor-about-palantir-stock)
* [‘No Need to Rush In,’ Says Oppenheimer About Tesla Stock](https://www.tipranks.com/news/no-need-to-rush-in-says-oppenheimer-about-tesla-stock)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/shield-therapeutics-grants-share-options-to-new-ceo-to-strengthen-market-position)
